RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
TaiGen Biotech, a Taipei infectious disease company, has started a China Phase III trial of a combination treatment for chronic hepatitis C. In 2016, TaiGen formed a $102 million JV with YiChang HEC ChangJiang to develop the oral dual-drug, direct-acting antiviral HCV treatment. TaiGen contributed China rights to furaprevir for a 49% stake in the JV, while HEC transferred China rights for yimitasvir, plus an undisclosed amount of cash, for 51% ownership. The companies expect to complete the Phase III trial in 2020.
Source: China Biotoday
